Novartis' Gleevec represents a huge victory in the war against cancer. The drug, approved by the Food & Drug Administration in May for chronic myeloid leukemia (CML), is the first of a huge number of oncology drugs in development that precisely target cancer cells without harming healthy tissue. CML is a rare disease, but the drug also shows promise against stomach, lung, and brain cancers (877 453-3832, gleevec.com).
Previous | Next